International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

FEV 1, COPDCompEx event risk and mucus plugging possibly improve with receipt of anti-IL-33 monoclonal antibody tozorakimab. Some patient subgroups achieved more benefits in lung function with ...

The drugmaker moved tozorakimab, an anti-IL-33 monoclonal antibody, into phase 2b in DKD in 2019 in response to evidence that inflammation plays a role in disease. Biomarkers of inflammation ...

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 ...

AstraZeneca progressed tozorakimab into Phase IIb for DKD in 2019, as there was evidence that increased inflammation is associated with deterioration in renal function. In addition, the trial ...